Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL, Odriozola J, Rodriguez-Salvanés F, Giraldo P, García-Laraña J, Ferro MT, Benítez E, Pérez-Pons C, Giralt M, Escribano L, Lavilla E, Miguel A, Areal C, Pérez-Encinas M, Abad A, Maldonado J, Massagué I, Fernández-Rañada JM. Steegmann JL, et al. Haematologica. 1999 Nov;84(11):978-87. Haematologica. 1999. PMID: 10553157 Clinical Trial.
Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.
Steegmann JL, Moreno G, Aláez C, Osorio S, Granda A, de la Cámara R, Arranz E, Reino FG, Salvanés FR, Fernández-Rañada JM, Muñoz C. Steegmann JL, et al. Among authors: fernandez ranada jm. Haematologica. 2003 Jul;88(7):762-8. Haematologica. 2003. PMID: 12857554 Clinical Trial.
Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
Steegmann JL, Requena MJ, Casado LF, Pico M, Peñarrubia MJ, Ferro MT, Resino M, Fernandez-Rañada JM. Steegmann JL, et al. Am J Hematol. 1996 Nov;53(3):169-74. doi: 10.1002/(SICI)1096-8652(199611)53:3<169::AID-AJH4>3.0.CO;2-X. Am J Hematol. 1996. PMID: 8895687 Free article.
156 results